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OBJECTIVE—Diabetic patients often experience visceral hyper-
sensitivity and anorectal dysfunction. We hypothesize that the
enhanced excitability of colon projecting dorsal root ganglia
(DRG) neurons observed in diabetes is caused by a decrease in
the amplitude of the transient A-type K
+ (IA) currents resulting
from increased phosphorylation of mitogen-activated protein
kinases (MAPK) and reduced opening of Kv4.2 channels.
RESEARCH DESIGN AND METHODS—We performed patch-
clamp recordings of colon projecting DRG neurons from control
and streptozotocin-induced diabetic (STZ-D) rats. Western blot
analyses and immunocytochemistry studies were used to eluci-
date the intracellular signaling pathways that modulate the IA
current. In vivo studies were performed to demonstrate that ab-
normal MAPK signaling is responsible for the enhanced viscero-
motor response to colorectal distention in STZ-D rats.
RESULTS—Patch-clamp studies demonstrated that IA current
was diminished in the colon projecting DRG neurons of STZ-D
rats. Western blot analysis of STZ-D DRG neurons revealed
increases in phosphorylated MAPK and KV4.2. In diabetic DRG
neurons, increased intracellular Ca
2+ ([Ca
2+]i), protein kinase C
(PKC), and MAPK were involved in the regulation of IA current
through modulation of Kv4.2. Hypersensitive visceromotor re-
sponses to colorectal distention in STZ-D rats were normalized
by administration of MAPK inhibitor U0126.
CONCLUSIONS—We demonstrated that reduction of the IA cur-
rent in STZ-D DRG neurons is triggered by impaired [Ca
2+]i ion
homeostasis, and this in turn activates the PKC-MAPK pathways,
resulting in decreased opening of the Kv4.2 channels. Hence, the
PKC-MAPK–Kv4.2 pathways represent a potential therapeutic tar-
get for treating visceral hypersensitivity in diabetes. Diabetes
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P
atients with long-standing diabetes often dem-
onstrate visceral hypersensitivity and anorectal
dysfunction. This may result in altered bowel
habits, rectal urgency, and diarrhea (1–4). The
pathophysiology of these conditions remains unclear.
Previous studies suggest that diabetes-induced sensory
neuropathies may be the consequence of increased activity
of primary afferent ﬁbers leading to an increased excit-
atory tone in the spinal cord (5). The spectrum of inter-
acting ionic currents in different types of neurons appears
to be important in determining the excitability of sensory
neurons (6,7). The transient A-type K
+ (IA) current is an
important determinant of neuronal excitability. This cur-
rent participates in the transduction of graded stimulating
currents into graded ﬁring rates (8). Kv4.2 channels, which
are the primary molecular correlates of the IA current in
sensory neurons, are prime targets for modulation (9,10).
Sensory neuropathies in diabetes are associated with ab-
normal signaling in the intracellular Ca
2+ ([Ca
2+]i)p a t h w a y
in the dorsal root ganglia (DRG) neurons. Enhanced inﬂux
of Ca
2+ via multiple high-threshold Ca
2+ currents and/or
abnormal [Ca
2+]i uptake by endoplasmic reticulum occurs
in sensory neurons of several models of diabetes (11–15).
Increased [Ca
2+]i signaling has also been implicated in the
pathogenesis of a variety of neurodegenerative disorders
(16). We hypothesize that diabetes is associated with
Ca
2+-mediated activation of mitogen-activated protein kinases
(MAPK) that modulates the IA current in the DRG neurons.
The reduction in IA current results in enhanced neural
excitability, which may cause rectal hypersensitivity. To
test this hypothesis, we examined how diabetes-evoked
changes in [Ca
2+]i homeostasis modulate the excitability of
distal colon projecting DRG neurons. We demonstrated
that diabetic visceral hypersensitivity in the rectum is
mediated by an abnormal IA current resulting from in-
creased phosphorylation of MAPK in DRG neurons. This
decreases the opening of Kv4.2 channels and reduces the
amplitude of IA current. The increased neuronal excit-
ability appears to be responsible for rectal hypersensitivity
in diabetes.
RESEARCH DESIGN AND METHODS
All procedures were performed in accordance with the National Institutes of
Health guidelines and with the approval of the University Committee on Use
and Care of Animals at the University of Michigan.
Generation of streptozotocin-induced diabetic rats. Diabetes was induced
in Sprague-Dawley rats (200 g) by an intraperitoneal injection of streptozotocin
(STZ; 50 mg/kg) dissolved in sodium citrate buffer. Diabetes was conﬁrmed
2–12 weeks later by measurement of tail vein blood glucose levels with Glu-
cotide strips (Bayer Diagnostics, Puteaux, France). Only rats with a ﬁnal blood
glucose level .15 mmol/L (300 mg/dL) were included in the study. Control rats
received only sodium citrate buffer.
Retrograde tracing of DRG neurons. Normal (n = 11) and STZ-induced
diabetic (STZ-D; n = 15) male rats were deeply anesthetized with a mixture of
halothane in air, as described previously (17,18). After a laparotomy, the ret-
rograde tracer DiI was applied to the distal colon. To conﬁne the dye to the
application site, DiI crystals were embedded in a fast-hardening epoxy resin
that was allowed to harden for approximately 5 min. The wound was closed
with nylon sutures (4-0). The animals were allowed to recover for a 15–20-day
period before being killed for the harvesting of L6–S2 DRG neurons.
Isolation and culture of DRG neurons. DRG neurons from L6–S2 spinal
segments were surgically removed from rats anesthetized with ketamine (250
mg/kg) and xylazine (25 mg/kg). The ganglia were digested for 60 min at 37°C
in Dulbecco’s modiﬁed Eagle’s media (DMEM; Invitrogen, Carlsbad, CA)
containing 1 mg/mL dispase (Roche, Nutley, NJ) and 1 mg/mL collagenase type
I (Invitrogen). Neurons were dispersed by gentle trituration through Pasteur
pipettes and washed with DMEM. Droplets of media containing isolated DRG
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ORIGINAL ARTICLEneurons were transferred onto coverslips coated with poly-D-lysine for 30 min.
To mimic the ambient glucose concentrations in control and diabetic rats,
isolated DRG neurons from control and STZ-D rats were maintained in 5 or
15 mmol/L glucose containing DMEM/F12 media, respectively, supplemented
with 10% fetal calf serum (Invitrogen) and gentamycin (100 units/mL; In-
vitrogen) at 37°C in a 5% CO2 atmosphere. Electrophysiological recordings on
primary neuron cultures were performed within 24 h.
Patch-clamp electrophysiology. Labeled DRG neurons were identiﬁed using
a Nikon Ti-S microscope equipped with TRITC epiﬂuorescence ﬁlters. Whole-
cell or perforated patch recordings were performed using borosilicate glass
electrodes with resistance between 3and 6mol/LV (A-M Systems,Sequim, WA)
backﬁlled with a saline solution composed of 130 mmol/L potassium gluco-
nate, 10 mmol/L HEPES, 10 mmol/L EGTA, 1.0 mmol/L MgCl2, 2.5 mmol/L
CaCl2, 1.0 mmol/L adenosine triphosphate, and 0.3 mmol/L guanosine tri-
phosphate. Current and voltage recordings were obtained from discrete iso-
lated DRG neurons using the Axopatch 200B patch-clamp ampliﬁer (Axon
Instruments, Foster City, CA). The signals were digitized using the analog-to-
digital converter Digidata 1322B (Axon Instruments) and then stored and
analyzed on a personal computer running pClamp 10 software. The membrane
resistance of DRG neurons was calculated in current clamp mode by mea-
suring membrane potential changes in response to the current step of 20-pA
amplitude and lasting 500 ms. The resting membrane potential (VM) of each
cell was recorded from the voltage meter in current clamp mode at the be-
ginning of each experiment. An action potential (AP) was evoked by injecting
depolarizing current pulses while keeping the DRG neurons at approximately
260 mV by a constant current injection. The amplitude of command current
was increased in 10-pA increments until it reached sufﬁcient intensity to ini-
tiate an AP. AP duration was measured at half-peak amplitude. The amplitudes
of IA and IH, a slowly activating current evoked by hyperpolarization, were
measured in voltage clamp mode. IH was evoked by a hyperpolarizing voltage
command to 2130 mV from a holding potential of 260 mV. IA was evoked on
repolarization to a holding potential (260 mV) from the test hyperpolarization
to 2130 mV. The amplitude was measured at its peak current.
Measurement of [Ca
2+]i. DiI-labeled neurons were identiﬁed by the in-
tracellular presence of red label using TRITC ﬁlter. These DRG neurons plated
on glass coverslips were incubated in physiological saline containing 2 mmol/L
Fura-2-acetoxymethyl ester (Molecular Probes, Eugene, OR) for 15 min at 37°C.
The dish volume was subsequently reduced to 0.5 mL, and the cells were
equilibrated in physiological saline at a ﬂow rate of 1 mL/min in a heated
chamber (30–33°C). After .10 min, the ﬂuorescence of individual DRG neu-
rons was elicited by alternating excitation wavelengths of 340 and 380 nm (Till
Polychrome V; Till Photonics, Gräfelﬁng, Germany) using a 410-dichroic
longpass beamsplitter and a D510/80-wide band emission ﬁlter. Neuron images
were captured at 510 nm using a Nikon camera. The camera and mono-
chromator were controlled by NIS-Elements imaging software, and the con-
centrations of [Ca
2+]i were calculated online. The software allows subtraction
of background ﬂuorescence. The actual [Ca
2+]i was calculated from the ratio
of ﬂuorescence recorded at excitation wavelengths of 340 and 380 nm.
Western blot analyses. DRG neurons from L6–S2 were lysed and centrifuged
at 14,000g for 10 min. Protein samples were then run on Ready Gel 12% Tris-
HCl for 1.5 h at 80 V. Proteins were then transferred to nitrocellulose mem-
branes for 1 h at 80 V. The membranes were blocked with StartBlock buffer
T20 for 1 h at room temperature, probed with primary antibodies that recognize
either anti-MAPK or anti-phospho–p44/p42 MAPK (extracellular signal-regulated
kinase [Erk]1/2) after activation by dual phosphorylation at Thr202/Tyr204 (Cell
Signaling Technology, Danvers, MA). The later studies were performed at
1:1,000 dilution at 4°C overnight and then washed in Tris-buffered saline with
0.1% Tween 20 for 1 h. To measure the levels of Kv4.2 channels, we used anti-
Kv4.2 or anti-phospho–Kv4.2, which detects phosphorylation on Thr602 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:1,000 dilution at 4°C overnight
and then washed in Tris-buffered saline with 0.1% Tween 20 for 1 h. The mem-
branes were probed with corresponding horseradish peroxidase–conjugated
secondary anti-rabbit antibodies at 1:2,000 dilution. Protein bands were detected
with enhanced chemiluminescence Western blotting reagents (Thermo Fisher
Scientiﬁc, Rockford, IL). The resulting bands were scanned with an Epson
2400 printer and analyzed using the ImageJ program.
Immunohistocytochemistry studies. Immunohistocytochemistry studies to
localize MAPK/Erk(1/2), Kv4.2, and neuroﬁlament marker (NF200) were per-
formed in L6–S2 DRG neurons from control rats (n = 3) and STZ-D rats (6–8
weeks after induction of diabetes; n = 3). After anesthesia with urethane,
a transcardial perfusion was performed with ice-cold, heparinized PBS and
subsequently with a ﬁxative containing 4% paraformaldehyde, 0.2% picric acid,
and 0.35% glutaraldehyde in phosphate buffer (0.1 mol/L, pH 7.4). The DRG
neurons were removed and placed in the same ﬁxative for 2 h at room tem-
perature and then in 25% sucrose in PBS (0.1 mol/L) overnight at 4°C. Sections
(5–10 mmol/L) of the DRG neurons were incubated in 5% normal donkey se-
rum in PBS for 1 h at room temperature. Labeling was performed using mouse
monoclonal anti-Kv4.2 (K57/1; University of California at Davis, National
Institutes of Health NeuroMab facility, Davis, CA) dilution 1:500 and rabbit
anti-phospho–p44/42 MAPK(Erk1/2) (Thr202/Tyr204; Cell Signaling Technology)
dilution 1:500. The primary antibodies were diluted in PBS containing 2% nor-
mal donkey serum and 0.3% Triton X-100, and tissues were incubated overnight
at room temperature. The tissues were washed in PBS and exposed for 1 h to
species-speciﬁc AlexaFluor 488 (Molecular Probes) or cyanine 3-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove,
PA) diluted with PBS containing 0.3% Triton X-100. Speciﬁcity of immunohis-
tochemical labeling was veriﬁed with the omission of primary antibodies, and
staining was performed using only secondary antibodies. The sections were
coverslipped and then sealed.
Visceromotor responses to graded colorectal distention. Measurement of
visceral sensitivity in animals was mainly based on brain stem reﬂexes, which
have been described as pseudoaffective responses (19). The visceromotor
responses were recorded by quantifying a reﬂex contraction of the abdominal
musculature induced by colorectal distention (CRD). The animals were
anesthetized with a mixture of xylazine and ketamine (13 and 87 mg/kg body
wt, respectively). Electromyography electrodes were implanted into the ex-
ternal oblique pelvic muscles 4–6 days before the beginning of the experi-
mental procedures. The skin was sutured over the strain gauge, and the lead
wires were looped around the animal’s ﬂank and secured with a single suture
in the skin. During the experiment, the strain gauge was connected by way of
a shielded cable to a chart recorder to monitor the number of abdominal
muscle contractions. A latex balloon (7 cm long) was be inserted into the
colon through the rectum. Graded-pressure CRD was produced by rapidly
injecting warm saline (37°C) into the colonic balloon over 1 s and maintaining
the distention for 20 s. Pressure was regulated with a distention control device
and monitored by use of a pressure transducer. Graded-intensity stimulation
trials (20–40–60–80 mmHg CRD) were conducted to establish stimulus-response
FIG. 1. Representative voltage-clamp recordings show three types of
DRG neurons with the expressed IH, IA, or both IH and IA currents.
TABLE 1
Statistical analyses of the three different DRG neuronal types
H-type A-type A–H-type
Rin (MV) 162 6 28# 255 6 55* 373 6 70*
Vm (mV) 61.2 6 0.7 62.1 6 1.8 61.6 6 1.5
AP
Amplitude (mV) 92 6 4.5 90.1 6 3.7 98 6 8.4
Duration at 50% (ms) 1.3 6 0.3# 2.2 6 0.4* 3.6 6 1.0*
Threshold (pA) 240 6 59# 54 6 19* 233 6 86*#
Amplitude (pA)
IH 353 6 61# Not detected* 62 6 17*#
IA Not detected# 411 6 57* 54 6 14*#
Size (mm) 40.7 6 7.3 29 6 3.2 20 6 1.5*#
%( n) 40 (32/80) 45 (36/80) 15 (12/80)
Results are expressed as mean 6 SE. The signiﬁcance of differences
was determined with the Student t test, assuming unequal variance
(P , 0.05), from three different experiments. *Signiﬁcantly different
from H-type. #Signiﬁcantly different from A-type.
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baseline period, a 20-s distention period, and a 20-s post-CRD termination pe-
riod with a 4-min interstimulus interval. The responses were considered stable if
there was less than 20% variability between two consecutive trials of CRD at
60 mmHg. The results of electromyography were ampliﬁed and ﬁltered
(5,0003,3 0 0 –5,000 Hz; A-M Systems), digitized, and integrated by using the
SPIKE2/CED 1401 data-acquisition interface. Spike bursts higher than 0.3 mV
were regarded as signiﬁcant and were, therefore, used to estimate the pain
response.
Visceromotor responses were performed in both control and U0126-treated
rats. U0126 was administered either intravenously (10 mg/kg) or intrathecally
(5 mg in 0.5 ml of saline). For intrathecal administration, rats were anes-
thetized, and a 25-gauge, 1-inch needle connected to a 20-ml Hamilton syringe
was inserted into the subarachnoid space between lumbar vertebrate S1 and
S2 until a tail-ﬂick was elicited. The syringe was held in the position for a few
seconds after injection.
Statistical analysis. Data were presented as mean 6 SEM; n is the number of
samples. The software package InStat 3 (GraphPad Software, Inc., San Diego,
CA) was used for data analysis. The x
2 tests were used for analyses of con-
tingency tables with more than three categories. For analysis of differences
between means, one-way ANOVA with Student-Newman-Keuls test was used.
Results were considered statistically signiﬁcant when P , 0.05.
RESULTS
Basic electrophysiological properties of DRG neurons.
Whole-cell recordings were obtained from 80 DRG neu-
rons, 45 of which were labeled after placement of DiI in
the distal colon. DRG neurons were divided into three
groups on the basis of expression of fast inactivation of IA
and IH currents. The H-type neurons, comprising 45% of
the total population of isolated DRG neurons, were char-
acterized as a group of neurons that expressed IH and
no IA current. In comparison, the A-type neurons (40%)
expressed IA and no IH current, and the A–H-type group
(15%) expressed both IH and IA currents (Fig. 1). The
general electrophysiological properties of these three
groups of neurons are provided in Table 1.
No signiﬁcant differences in neuronal properties were
observed between DiI-labeled and nonlabeled neurons
(data not shown).
Effect of diabetes on IA current in DRG neurons.
Among the three groups of distal colon projecting neu-
rons, only A-type neurons appeared to be affected by di-
abetes as demonstrated in STZ-D rats (6–8 weeks after
induction of diabetes) (Fig. 2A). The density of IA current
was signiﬁcantly smaller in STZ-D A-type neurons when
compared with controls (Fig. 2B). STZ-D did not alter the
IA current-voltage relationship (Fig. 2C).
Increase in phosphorylation of MAPK(Erk1/2) and
Kv4.2 in diabetic DRG neurons. The Kv4.2 channel that
mediates the IA current is speciﬁcally phosphorylated at
Thr602 by MAPK(Erk1/2), resulting in decreased opening
of the channel and neuronal depolarization (20,21). We
investigated whether the phosphorylation of MAPK iso-
forms Erk1/2 and Kv4.2 were enhanced with the de-
velopment of diabetes. Immunoblot analysis with speciﬁc
anti-phospho–44/42 MAPK(Erk1/2) and anti-phospho–Kv4.2
revealed a progressive increase in the levels of phosphor-
ylation of MAPK(Erk1/2) and Kv4.2 in diabetic DRG neu-
rons. At 8 weeks, the phosphorylated-MAPK (p-MAPK) and
phosphorylated-Kv4.2 (p-Kv4.2) levels were 240 6 19 and
265 6 31% above the levels in nondiabetic age-matched
DRG neurons (P , 0.05; Fig. 3). In contrast, the levels
of nonphosphorylated Kv4.2 did not change with diabetes
FIG. 2. Effects of STZ-induced diabetes on the amplitude of IA current in A-type DRG neurons. A: Representative recordings of IA currents in
control and STZ-D DRG neurons. B: Summary histogram shows that the amplitude of IA current normalized to cell capacitance (Cm) was signif-
icantly reduced in STZ-D (6–8 weeks after the induction of diabetes; n = 28) neurons compared with controls (n = 24). *P < 0.05 compared with
aged-matched controls. C: Normalized IA amplitude-voltage relationships demonstrate that STZ-D (n = 11) did not affect inactivation curve
compared with control (n = 11).
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ulation of DRG neurons from control rats expressed
the Kv4.2 channel (Fig. 4A-C). However, only a small
fraction (3 6 1%) of DRG neurons from the control group
was immunoreactive to anti-p-MAPK(Erk1/2). This ﬁnd-
ing is consistent with that reported by Averill et al. (22).
In STZ-D rats (8 weeks after induction of diabetes), the
number of p-MAPK immunoreactive neurons was ;12
times higher (36 6 5%) compared with that in control rats
(Fig. 4D; P , 0.05). These ﬁndings indicate that phos-
phorylation of MAPK(Erk1/2) and Kv4.2 occurs in diabetic
DRG neurons, raising the possibility that this pathway may
be involved in the pathogenesis of diabetic sensory neu-
ropathy.
[Ca
2+]i modulates the amplitude of the IA current.
Studies from animal models of diabetes and from di-
abetic patients reveal that [Ca
2+]i is increased in most tis-
sues, including DRG neurons (11,20). To conﬁrm and
expand these observations, we measured the levels of
resting [Ca
2+]i in retrograde-labeled DRG neurons isolated
from control and STZ-D rats. The level of [Ca
2+]i was sig-
niﬁcantly increased in DRG neurons from STZ-D rats, 8
weeks after the induction of diabetes (Fig. 5A). We next
investigated the effects of [Ca
2+]i on the amplitude of IA
current. Application of ionomycin (1 mmol/L), a Ca
2+ ion-
ophore, inhibited the amplitude of IA by ;50% in normal
retrograde-labeled DRG neurons (Fig. 5B and C). In con-
trast, superfusion of retrograde-labeled DRG neurons with
Ca
2+-free solution resulted in an increase of the IA ampli-
tude (Fig. 5D). These ﬁndings indicated that [Ca
2+]i modu-
lates the amplitude of IA. We next examined the hypothesis
that increased [Ca
2+]i acts via PKC to cause a reduction in
the amplitude of IA current. Retrograde-labeled A-type DRG
neurons from normal rats were dialyzed with a speciﬁc
PKC inhibitor, calphostin C (5 mmol/L), for 10–15 min
(n = 4). At the concentration of 5 mmol/L, calphostin C acts
as a speciﬁc inhibitor of PKC, which interacts with the
protein’s regulatory domain by competing at the binding site
of diaglycerol and phorbol ester. Calphostin C effectively
blocked the inhibitory effect of ionomycin, suggesting
that [Ca
2+]i inhibits IA current via a PKC-activated pathway
(Fig. 5E).
Intracellular pathways responsible for modulation of
IA current. Patch-clamp whole-cell recordings of isolated
distal colon projecting neurons showed that extracellular
application of phospholipase C (PLC) activator (1 mmol/L;
n = 6) inhibited the amplitude of IA by 82% (P , 0.05). PLC
activator is a novel sulfonamide compound that acts as
a cell permeable–speciﬁc activator of PLC. The effect of
the PLC activator was markedly attenuated by inclusion of
calphostin C (1 mmol/L; n = 6), a selective PKC inhibitor,
into the recording electrode (Fig. 5F). Furthermore, we
demonstrated that PKC activation by phorbol 12-myristate
13-acetate (PMA; 1 mmol/L; n = 5), a phorbol ester,
inhibited the amplitude of IA by 97% (P , 0.05). The effect
of PMA was blocked by simultaneous application of the
MAPK kinase inhibitor PD98059 (1 mmol/L; n = 4; Fig. 5F)
or U0126 (5 mmol/L; n = 3; data not shown). These data led
us to conclude that the activation of the PKC-MAPK
pathway by increased [Ca
2+]i leads to subsequent in-
hibition of the amplitude of IA current.
MAPK kinase inhibitor restores the amplitude of IA in
diabetic DRG neurons. If the activation of MAPK is
a necessary step for the phosphorylation of the Kv4.2
channel leading to inhibition of IA current (22,23), in-
hibition of this protein kinase cascade should attenuate the
FIG. 3. Western blot demonstration of increased levels of phosphorylated-MAPK (p-MAPK; Erk1/2) and phosphorylated-Kv4.2 (p-Kv4.2) in DRG
neurons of STZ-D rats. A: Immunoblots show increased phosphorylation of Erk1 and Erk2 in DRG homogenates from STZ-D rats 8 weeks after the
induction of diabetes compared with age-matched control rats. The immunoreactive bands for MAPK and p-MAPK were normalized against
a loading control (actin; upper panel). Summary histogram shows diabetes duration–dependent phosphorylation of MAPK(Erk1/2) in DRG neurons
(lower panel; n = 5 for each group). B: Immunoblots show increased phosphorylation of Kv4.2 channel in DRG homogenates from the same group of
diabetic rats compared with age-matched controls. Histogram shows diabetes duration–dependent phosphorylation of Kv4.2 in DRG neurons (lower
panel; n = 5 for each group). *P < 0.05 compared with aged-matched controls.
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show that MAPK is involved in diabetes-induced reduction
of IA amplitude, we examined the effects of MAPK kinase
(MEK) inhibitor U0126 on DiI-labeled DGR neurons
obtained from STZ-D rats 8 weeks after the induction of
diabetes. Extracellular superfusion of U0126 (5 mmol/L;
n = 5) signiﬁcantly increased the amplitude of IA (260 6
23%; P , 0.05; Fig. 6A and B). To demonstrate the role of
aK v4.2 subunit in the mediation of IA current, we mea-
sured the levels of both p-MAPK and p-Kv4.2 before and
after application of U0126. Western blot analyses showed
that 15-min treatment of STZ-D DRG primary neuronal
cultures with U0126 (5 mmol/L; n = 4) signiﬁcantly de-
creased the levels of both p-MAPK and p-Kv4.2 compared
with untreated cultures (Fig. 6C). Similar results were
obtained with another MAPK kinase inhibitor, PD98059
(data not shown).
In vivo administration of a MAPK inhibitor normalizes
colorectal hypersensitivity in diabetic rats. To provide
direct evidence that MAPKs contribute to the development
of visceral hypersensitivity in the distal colon of diabetic
rats, visceromotor responses to CRD were studied in nor-
mal (n = 6), STZ-D (8 weeks after STZ injection; n = 6), and
U0126-treated STZ-D rats (n =6 ) .As i g n i ﬁcant increase in
visceromotor responses occurred in STZ-D rats compared
with control rats after CRD of 20, 40, and 60 mmHg. We
used U0126 to inhibit MAPK activity in the DRG neurons,
but not in the central neurons. U0126 does not cross the
blood-brain barrier, but it can access DRG neuron somas
and afferent ﬁbers (24). Intravenous injection of U0126
(10 mg/kg; n =6 )i nS T Z - Dr a t ss i g n i ﬁcantly suppressed
visceromotor responses to CRD within 15 min (Fig. 7A;
P , 0.05). Similar results were obtained with intrathecal
administration of U0126 (5 mgi n0 . 5ml saline; Fig. 7B; P ,
0.05). In contrast, intravenous injection of U0124, an
inactive form of U0126, did not have any signiﬁcant ef-
fect on the enhanced visceromotor responses to CRD in
STZ-D rats (n = 3; data not shown). We also showed that
intravenous administration of U0126 markedly reduced
phosphorylation of Erk1/2 and Kv4.2 in L6–S2 DRG neu-
rons (Fig. 7). These data indicate that activation of the
MEK-MAPK/ERK pathway in DRG neurons plays an im-
portant role in the mediation of visceral hypersensitivity
induced by diabetes.
DISCUSSION
It is well established that the diabetic state can increase
the excitability of nociceptive afferents, resulting in painful
diabetic neuropathy and mechanical allodynia in diabetic
patients, as well as in diabetic animal models (3). On the
other hand, it also has been reported that diabetes impairs
the detection of lower intensity coetaneous stimuli. This
effect is mediated by pelvic afferent nerve endings, which
underlie low-threshold mechanosensitivity (1). The differ-
ent effects of diabetes in different groups of DRG neurons
and the variable duration of diabetes used in different
studies may contribute to these seemingly opposite ﬁndings.
The descending colon and rectum in the rat are innervated
by visceral afferents that project in the pelvic (para-
sympathetic) nerve to the L6–S2 spinal segments (17,25).
In this study, we showed that visceromotor responses to
CRD were signiﬁcantly higher in STZ-D rats 8 weeks after
the induction of diabetes. This observation was consis-
tent with our in vitro observations using isolated distal
colon projecting DRG neurons, suggesting the development
of visceral hypersensitivity.
Our electrophysiological data indicate the presence of
distinct populations of DRG neurons that probably serve
different physiological functions. Variation in IH, IIR (inward
FIG. 4. STZ-induced diabetes increases the number of p-MAPK(Erk1/2) immunoreactive DRG neurons. Photomicrographs of merged images show
colocalization of anti-Kv4.2 (green) and anti-p-MAPK (red) immunoreactivities from control (A) and STZ-D (B) rats DRG neurons, respectively.
Note that a large population of DRG neurons from control rats expressed the Kv4.2 immunoreactivities, but only a small fraction of DRG neurons
was immunoreactive to anti-p-MAPK (Erk1/2; arrows). Note that the number of p-MAPK immunoreactive neurons was ;12 times higher in STZ-D
DRG compared with control DRG. C: Photomicrograph showing background immunoreactivities of secondary antibodies anti-mouse (green) and
anti-rabbit (red) when ﬁrst antibodies were omitted. D: Summary histogram showing the fractions of p-MAPK-positive neurons in control and STZ-D
DRG. *P < 0.01, compared with control; n = 3. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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neurons of different sizes (6,7). Our data also indicated that
small- and medium-sized DRG neurons preferentially ex-
press IA current. These small- and medium-sized DRG
neurons are the primary sensory neurons responsible for
pain sensation (9,26). Our STZ-D rat model showed that
A-type DRG neurons were affected by diabetes, resulting in
the reduction of the amplitude of IA current and enhanced
excitability.
Peripheral axons and somas of sensory DRG neurons
exist outside the protection of the blood–nerve barrier;
thus, they are directly exposed to the high glucose levels
in diabetes (5). Schneider et al. (27) reported that hyper-
glycemia increased the depolarizing after-potentials that
caused hyperexcitability of sensory DRG neurons. Our
studies further identiﬁed that IA currents were reduced in
diabetic DRG neurons.
Several studies have shown that the level of cytosolic
Ca
2+ increases with the onset of diabetes (12–15). It has
been suggested that elevation of the [Ca
2+]i level observed
in spinal sensory neurons in rodent models of diabetes is
the result of increased Ca
2+ release from internal stores
and impaired Ca
2+ resequestration (14,15). Diabetes is also
associated with increased amplitude in multiple voltage–
dependent Ca
2+ currents (13–15). Disturbances in the
homeostasis of [Ca
2+]i have been proposed to be a com-
mon pathway in the pathogenesis of neurologic compli-
cations of diabetes (12). Our studies showed that the level
of [Ca
2+]i was signiﬁcantly increased in diabetic DRG
neurons, and this was associated with a reduction of IA
current.
We propose that reduction of IA current in DRG neurons
of STZ-D rat is triggered by impaired [Ca
2+]i homeostasis
and activation of the PKC-MAPK pathway reducing the
opening of Kv4.2 channels. This hypothesis was supported
by experiments showing that administration of a MAPK
kinase inhibitor normalized the levels of p-MAPK and p-Kv4.2
and restored the amplitude of IA.
The expression of MAPKs is altered by high glucose and
oxidative stress in cultured sensory neurons from diabetic
rats (28–30). Activation of MAPK plays a key role in the
regulation of central sensitization resulting in long-term
pain hypersensitivity (30,31,32). Daulhac et al. (33) re-
ported that the development of mechanical hyperalgesia,
a symptom of diabetic neuropathy, in STZ-D rats corre-
lated with an increase in MAPK phosphorylation in the
spinal cord and DRG neurons. However, it is unknown
whether this abnormal intracellular signaling occurs in
visceral hypersensitive state in diabetic rat models. We
conﬁrmed and expanded these observations to DRG neurons
FIG. 5. [Ca
2+]i modulates the amplitude of IA current in DRG neurons. A: Basal [Ca
2+]i in retrograde-labeled DRG neurons from control (n = 26) and
STZ-D (n = 25) animals. *P < 0.05 from control. B: Superimposed current traces of IA recorded from normal DRG neurons in control conditions and
during extracellular superfusion of ionomycin (1 mmol/L). C: Summary histogram shows the effect of ionomycin on the amplitude of IA current.
*P < 0.05 from control. D: Time course of the amplitudes of IA current plotted against time shows that bath application of Ca
2+-free extracellular
media resulted in a progressive increase in the amplitude of IA current. The insets show IA current recorded in control (upper left) and 10 min after
superfusion of Ca
2+-free bath media (upper middle). E: Time course of the amplitudes of IA current plotted against time shows that dialysis of the
recorded neuron with PKC inhibitor calphostin C resulted in an increase in amplitude of IA, which became stable in 10 min (a; upper left inset). In
the presence of calphostin C, extracellular superfusion of inomycin (1 mmol/L) did not induce a change in the amplitude of IA current (b; upper
right inset) and application of 4-AP (4-aminopyridine) completely abolished the amplitude of IA current. Inhibition of IA current by PKC is MAPK
(Erk1/2)-dependent. F: Summary histogram shows the effects of PLC activator (1 mmol/L) and PKC activator PMA (1 mmol/L) on IA current in
control and in the presence of PKC inhibitor (calphostin C; 1 mmol/L) and MAPK kinase inhibitor (PD98059; 1 mmol/L), respectively. *P < 0.05
from control.
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levels of both p-MAPK/Erk1/2 and p-Kv4.2 were detected
as early as the 8th week and increased with the pro-
gression of diabetes. Furthermore, we showed that stim-
ulation of the MAPK-PKC pathway reduced the opening of
Kv4.2 channels, resulting in a reduction of the amplitude of
IA current and increased excitability. This ﬁnding should
be contrasted with a recent study by Cao et al. (34) who
reported that a decrease in IA current was accompanied by
a decreased gene expression in Kv4.2 in painful diabetic
neuropathy. Our studies showed similar reduction of IA
current but an increase in phosphorylated Kv4.2 and no
change in total protein expression. It is not uncommon
that the levels of mRNA do not always correlate with the
protein levels.
We provide direct evidence that MAPK contribute to the
development of visceral hypersensitivity in diabetic rats.
Eight weeks after the induction of diabetes, signiﬁcant
increase in visceromotor responses occurred in STZ-D rats
after CRD of 20, 40, and 60 mmHg. This indicates the de-
velopment of allodynia and hyperalgesia with a time
course consistent with the increased expression of phos-
phorylated MAPK and Kv4.2. Most importantly, the en-
hanced visceromotor responses to colorectal distension in
STZ-D rats were normalized by intravenous as well as in-
trathecal administration of the MAPK inhibitor U0126. It is
interesting to note that systemic administration of U0126
in diabetic rats reduced visceromotor responses to values
below those observed in normal rats. This suggests that
the PKC-MAPK pathways in the DRG may play an impor-
tant role to regulate rectal sensitivity even under normal
physiological conditions.
In conclusion, we provide evidence for the ﬁrst time that
diabetic visceral hypersensitivity is mediated by abnormal
IA current resulting from increased phosphorylation of
MAPK and Kv4.2 in DRG neurons. Our in vitro studies also
provide evidence that increased [Ca
2+]i contributes to
DRG neuronal excitability by activation of the PKC-MAPK
pathway, resulting in decreased opening of Kv4.2 channels.
These data suggest that the PKC-MAPK pathway repre-
sents a potential therapeutic target for the treatment of
visceral hypersensitivity in diabetes.
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